Grant name: Biology of Bladder Cancer (R21 Clinical Trial Optional)
Funding organization: National Institutes of Health (NIH)
Total funding amount: Up to $275,000
Duration: Maximum of 2 years
Primary objective: Investigate the biology and underlying mechanisms of bladder cancer
Key stakeholders: National Cancer Institute (NCI), researchers in bladder cancer biology
Funding source: NIH
Funding type: Grant
Significance: Addresses a significant health problem with high incidence and recurrence rates
Grant frequency: Recurring
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits (with and without 501(c)(3) IRS Status)
For-Profit Organizations
Small Businesses
Local Governments
State Governments
County Governments
City or Township Governments
Special District Governments
Indian/Native American Tribal Governments (Federally Recognized and Other)
Federal Governments
U.S. Territory or Possession
Independent School Districts
Public Housing Authorities/Indian Housing Authorities
Faith-based or Community-based Organizations
Regional Organizations
Foreign Organizations
Understanding bladder cancer biology and mechanisms
Investigating molecular and cellular functions altered in cancer
Research areas of interest include normal bladder development, NMIBC prevention, and tumor heterogeneity
Expertise in bladder cancer biology and related fields
Involvement of co-investigators with relevant expertise outside bladder cancer is encouraged
Combined budget for direct costs may not exceed $275,000
No more than $200,000 may be requested in any single year
Open Date: January 16, 2025
Application Due Dates: February 16, 2025 and June 16, 2025
Expiration Date: September 08, 2025
Compliance with NIH Grants Policy Statement required
Registration in System for Award Management (SAM) and eRA Commons necessary
Applications must be submitted electronically via Grants.gov
Adherence to application instructions in the Research (R) Instructions is critical